Floatz logo

ly01005

Cancer of Prostate

Luye Pharma Group Ltd.Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

115 Active assets in the Cancer of Prostate cohort.

Asset / SponsorPhaseRating
LEUPROLIDE
Mayo Clinic
Phase 4BBB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Degarelix
Baptist Health South Florida
Phase 3BBB
Enzalutamide
Pfizer
Phase 4BBB
Abiraterone Acetate
Mayo Clinic
Phase 4BBB

View all 50 →

Same molecule, other indications

ly01005 is also rated in:

prostate cancerDormant
B
Indicative ·
61 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →